EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma

David König, Jürgen Hench, Stephan Frank, Laura Dima, Ivana Bratic Hench, Heinz Läubli

Pharmacology · 2022 · 107 (7-8) · 433-438

DOI: 10.1159/000524399 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pharmacology, online erschienen am 06.05.2022. Verfasst von David König und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, University Hospital Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioma. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 2 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High-grade glioma (HGG) and glioblastoma are the most common adult malignant brain tumors. The standard treatment consists of surgical resection followed by radiochemotherapy with temozolomide. The prognosis and the therapeutic options of these malignant brain tumors however are limited. Here, we describe a case of a patient with HGG with a previously unknown NTRK3 fusion that showed an extraordinary response to treatment with larotrectinib. This case supports regular testing for NTRK fusion proteins.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsGliomaAdultHumansPyrazolesPyrimidinesTreatment Outcome

Stichwörter der Autor:innen

Brain cancerGlioblastomaPrecision medicineTargeted therapyTumor agnostic

Substanzen

PyrazolesPyrimidineslarotrectinib

Autor:innen und Institutionen

  • Division of Medical Oncology, University Hospital Basel, Basel, Switzerland.
  • Department of Biomedicine, University of Basel, Basel, Switzerland.
  • Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
  • Bayer HealthCare Pharmaceuticals Inc., Basel, Switzerland.

Zitieren

APA

König, D., Hench, J., Frank, S., Dima, L., Bratic Hench, I., & Läubli, H. (2022). Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma. Pharmacology, 107(7-8), 433-438. https://doi.org/10.1159/000524399

Vancouver

König D, Hench J, Frank S, Dima L, Bratic Hench I, Läubli H. Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma. Pharmacology. 2022;107(7-8):433-438. doi:10.1159/000524399

BibTeX
@article{Knig2022,
  author = {König, David and Hench, Jürgen and Frank, Stephan and Dima, Laura and Bratic Hench, Ivana and Läubli, Heinz},
  title = {Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma},
  journal = {Pharmacology},
  year = {2022},
  volume = {107},
  number = {7-8},
  pages = {433--438},
  doi = {10.1159/000524399}
}
Kostenlos starten →